Veraxa Biotech AG (VRXA)
VRXA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | VRXA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | Not reported by the screener |
| SEC CIK | 0002079109 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Switzerland |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Based on this a ssessment, management has concluded that the Company has sufficient liquidity to fund its planned operations and meet its obligations as they become due for at least the twelve months from the date these consolidated financial statements are available to be issued, and that no substantial doubt exists about the Company's ability to continue as a going concern. 28 Cash flows for the years ended Decembe" | 20-F 2026-06-16 |
| Cash and burn | no XBRL financials | None on EDGAR |
| Shares outstanding | 141,407,813 (2026-06-10). | Cover page 2026-06-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grassi & Co., CPAs, P.C., Jericho, New York, United States | PCAOB Form AP 2026-06-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $83K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-04 |
| Latest annual report | 20-F | 2026-06-16 |
| Latest quarterly / interim | 6-K | 2026-10-15 |
Source: SEC EDGAR submissions feed, 56 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +16.8% |
| 1 month | -7.5% |
| 3 months | -41.3% |
| Year to date | -89.6% |
| 1 year | -89.4% |
| From 52-week high | -95.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| VRXAW | Veraxa Biotech AG Warrants | $0.0227 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
| SION | Sionna Therapeutics Inc. | $3.12 | -6.31% | $141.1M |
| ZNTL | Zentalis Pharmaceuticals Inc. | $1.60 | -5.88% | $157.2M |
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| BBOT | BridgeBio Oncology Therapeutics Inc. Common Stock | $1.98 | -7.48% | $158.9M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
| ADCT | ADC Therapeutics SA Common Shares | $1.25 | -6.72% | $159.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier